![]() |
|
|
Vol. 58, Issue 6, 1279-1286, December 2000
Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania
| |
Abstract |
|---|
|
|
|---|
Prostaglandin E2 (PGE2) couples to stimulation of adenylyl cyclase through two distinct G protein-coupled receptors designated EP2 and EP4. Although they have similar affinities for PGE2, the EP2 and EP4 receptors have distinct structural characteristics. EP2 is a 358-amino-acid protein with short third intracellular loop and C-terminal domains, whereas EP4 consists of 488 amino acids with a long third intracellular loop and a long cytoplasmic tail. The ability of the HA epitope-tagged receptors to undergo PGE2-induced internalization was examined by enzyme-linked immunosorbent assay and immunofluorescence microscopy after expression in human embryonic kidney 293 cells. The EP2 receptor did not internalize, whereas the EP4 receptor underwent rapid internalization. Truncation of the EP4 receptor after amino acid 350, which removes 138 residues, abolished internalization. Truncation after amino acid 369 markedly attenuated internalization, whereas truncation after amino acid 383 had little effect. Serine and threonine residues in the region 350 to 383 were mutated to determine their role in internalization. The mutants S370-382A, a full-length receptor containing six serine-to-alanine mutations in the region 370 to 382, and S354-369A, containing four serine mutations and one threonine mutation in the region 350 to 370, both internalized to the same extent as the wild-type. A further mutant, designated S354-382A, containing amino acid substitutions S354A, S359A, S364A, S366G, T369A, S370A, S371A, S374A, S377A, S379A, and S382A, also internalized to the same extent as the wild-type. We conclude that the C terminus of the EP4 receptor is involved in internalization; however, serine and threonine residues do not seem to be involved.
| |
Introduction |
|---|
|
|
|---|
PGE2
is an important autocrine mediator in the cardiovascular and other
systems (Campbell and Halushka, 1996
). PGE2 is a
potent vasodilator in the microvasculature, although it may also cause constriction at selected sites. It causes a fall in systemic blood pressure and an increase in blood flow to the heart; it increases blood
flow to the kidneys, leading to increased diuresis, natriuresis, and
kaluresis, and causes secretion of renin from the renal cortex. PGE2 exerts its actions through four distinct G
protein-coupled receptors, designated EP1, EP2, EP3, and EP4, that are
encoded by different genes (for a review, see Negishi et al., 1995
).
The EP1 receptor couples to phospholipase C, the EP2 and EP4 receptors couple to stimulation of adenylyl cyclase, and the EP3 receptor couples
to inhibition of adenylyl cyclase.
EP2 and EP4 receptors are widely distributed; both receptors are found
in uterus, spleen, and lung; the EP4 receptor is also present in small
intestine, thymus, pancreas, leukocytes, and kidney (Regan et al.,
1994
; Katsuyama et al., 1995
). There are no selective EP receptor
antagonists that can be used in studies to functionally distinguish the
two receptors. However, the selective EP2 receptor agonist butaprost is
not active at the EP4 receptor (Regan et al., 1994
; Nishigaki et al.,
1995
). Some actions of PGE2 have been assigned to
the EP4 receptor through use of butaprost. These include stimulation of
matrix metalloproteinase activities in RNK-16 cells (Zeng et al.,
1996
). In addition, EP4 has been identified as the receptor on T cells
responsible for PGE2-mediated desensitization of
the CCR5 receptor, which is a cofactor in HIV infection (Thivierge et
al., 1998
). Gene knockout of the EP4 receptor shows that it plays a key
role in closure of the ductus arteriosus at birth (Nguyen et al., 1997
,
Segi et al., 1998
).
Although they have similar affinities for PGE2,
and function similarly to activate adenylyl cyclase, the
EP2 and EP4 receptors have distinct structural
characteristics. EP2 is a 358-amino-acid protein with relatively short
third intracellular loop and C-terminal domains (Regan et al., 1994
).
On the other hand, EP4 consists of 488 amino acids, and has a long
third intracellular loop and a long cytoplasmic tail (An et
al., 1993
). The EP2 receptor does not undergo
agonist-induced, short-term desensitization, whereas EP4 desensitizes
rapidly (Nishigaki et al., 1996
; Bastepe and Ashby, 1997
; Bastepe and
Ashby, 1999
), within minutes. Both the EP2 and EP4 receptor undergo
down-regulation upon long term (>2 h) exposure to agonist. Hence,
although boundaries between the roles of the EP2 and EP4 receptors
remain to be clarified, agonist-induced short-term desensitization is a
significant regulatory element in EP4-mediated signaling, but not in
EP2-mediated signaling, so that EP2 may be involved in mediating
sustained actions of PGE2, whereas EP4 mediates
rapidly waning events.
In previous studies, we have shown that the C-terminal domain of EP4 is
essential for agonist-induced desensitization (Bastepe and Ashby,
1997
). By deletion mutagenesis we identified a 14-amino-acid stretch
containing six serine residues that is involved in short-term EP4
desensitization (Bastepe and Ashby, 1999
). We mutated the six serine
residues at positions 370, 371, 374, 377, 379, and 382 to alanine to
generate a mutant, designated hEP4-S370-382A, that retained the entire C-terminal domain of wild-type
EP4. Mutant hEP4-S370-382A
showed no desensitization, indicating that at least one of the six
serines located between positions 370 and 382 may be necessary.
In the present work, we have extended our studies to examine structural features involved in internalization of the EP4 receptor, and have shown that the EP2 receptor does not undergo internalization. We assayed internalization on epitope-tagged forms of the receptors by an ELISA and by confocal immunofluorescence microscopy. We examined agonist-induced internalization of the native EP4 receptor and of a number of truncated forms as well as mutant forms.
Our results indicate that the C terminus of the EP4 receptor is involved in sequestration in common with other G protein-coupled receptors; however, serine or threonine residues in the C terminus do not seem to be involved.
| |
Materials and Methods |
|---|
|
|
|---|
Construction of Epitope-Tagged EP4 Truncations and Mutants.
The cDNAs for the EP4 receptor, truncated forms of the receptor and the
mutant receptor S370-382A were prepared as described previously
(Bastepe and Ashby, 1999
). The EP2 and EP4 receptor constructs were
epitope-tagged by inserting the nine-amino-acid epitope (YPYDVPDYA) of
hemagglutinin between the N-terminal methionine and the second amino
acid of each by use of PCR. The 5' end of the PCR product carried a
HindIII site. The forward primer for the EP4 receptor was
5'-ATG AAG CTT ATC ATG TAC CCA TAC GAC GTC CCA GAC TAC
GCT TCC ACT CCC GGG GTC AAT-3', where the HindIII site
is indicated in bold and the HA-tag is underlined, and the reverse
primer was 5'-GGG ATG GAG CAG ATG A GC-3'. The forward primer for the
EP2 receptor was 5' CTA AAG CTT ATG TAC CCA TAC GAC
GTC CCA GAC TAC GCT GGC AAT GCC TCC AAT GAC TCC-3', where the
HindIII site is indicated in bold and the HA-tag is
underlined, and the reverse primer was 5'-TGT AGG CCT AAG GAT GGC AAA
GAC-3'. The PCR product included a SacII site located at
nucleotide 696 of the coding region allowing us to epitope tag
constructs already created with truncations and mutations in the
C-terminal domain that begin at the same SacII site and
stretch into the 3'end of the molecule. Each construct was
epitope-tagged by cutting with HindIII and SacII
and removing the 5' end of the receptor, which does not contain any of
the truncations or mutations. The HA epitope-tagged PCR product was ligated into the HindIII/SacII site. All
constructs were prepared in pUC18 (Life Technologies-BRL, Grand Island,
NY) and subcloned into the mammalian expression vector pCEP4
(Invitrogen, Carlsbad, CA) for transfection.
Site-Directed Mutagenesis.
Construction of a mutant
containing the amino-acid substitutions S354A, S359A, S364A, S366G,
T369A (designated S354-369A) in the full-length receptor was achieved
by oligonucleotide-directed mutagenesis according to the method of
Higuchi et al. (1988)
. Two overlapping fragments of EP4 were amplified
by PCR using Turbopfu DNA polymerase (Stratagene, La Jolla, CA) using
the flanking primers P1 = 5'-CCA CCG CGG CCG CCT CGG
TTG CCT CC-3' and P4 = 5'-GGA GGG CCC TAT TTA TTC ATA
TAC ATT TTT CTG ATA AGT TCA G- 3', and the following primers, which
incorporate the five mutations. P2 = 5'- GGC GGG GCC CGC AGG GAG
CGC GCC GGA CAG CAC TGC GCA GAC GGT CAA AGG GCA TCT TCT
3', and
P3 = 5'- AGA AGA TGC CCT TTG ACC GTC TGC GCA GTG CTG TCC GGC GCG
CTC CCT GCG GGC CCC GCC - 3'. PCR was carried out for 25 cycles with 1 min at 95°C, annealing for 1 min at 62°C, and elongating for 1 min
at 72°C. One of the PCR products extends from the unique
SacII site to nucleotide 1116 (underlined in P1) and the
other one from nucleotide 1095 to the ApaI site (underlined
in P4) adjacent to the termination codon. Small aliquots of the
overlapping PCR products were combined, denatured, reannealed, and
subjected to additional 25 cycles of PCR using primers P1 and P4. After
purification and restriction enzyme digestion with SacII and
ApaI, the resultant PCR product was substituted into the
corresponding region of HA tagged-EP4 receptor in pUC 18 and the
full-length construct subcloned into pCEP4 for transfection.
PCR of the Human Prostaglandin EP2 Receptor.
We obtained the
cDNA for the human EP2 prostaglandin receptor by RT-PCR of vascular
smooth muscle total RNA. The full-length EP2 PCR product was prepared
with primers containing a HindIII site located on the
forward primer and a BamHI site located on the reverse
primer and subcloned into the vector puC18. The cDNA was sequenced and
shown to be identical with the sequence of the EP2 receptor reported by
Oakley (1995)
. The EP2 cDNA was HA epitope tagged and cloned into the
expression vector pCEP4.
Expression in 293-EBNA Cells. EP4 receptors and constructs were transfected into 293-EBNA cells obtained from Invitrogen. This line is a derivative of HEK 293 cells that stably expresses EBNA1. 293-EBNA cells were grown in DMEM supplemented with 10% fetal bovine serum in the presence of 250 µg/ml G418 to maintain expression of the EBNA1 plasmid. The cells were stably transfected with EP4 or EP2 construct cDNAs in pCEP4 by use of Lipofectamine (Life Technologies) according to the manufacturer's instructions with 200 µg/ml hygromycin B for selection, and clonal cells isolated by serial dilution. Positive clones were identified by the HA-tagged ELISA assay and by measuring PGE2-induced cAMP formation, and maintained in medium containing 10% fetal bovine serum, 250 µg/ml G-418 sulfate and 200 µg/ml hygromycin B.
Determination of cAMP Formation.
To determine whether
selected clones produced cAMP in response to
PGE2, clonal cells grown in six-well, 35-mm
culture plates were labeled overnight with 2 µCi/ml of
[3H]adenine (25 Ci/mmol). Labeling medium was
removed, and cells incubated for 10 min with fresh medium containing 2 mM IBMX. Cells were treated with 100 nM PGE2 for
15 min in the presence of 2 mM IBMX. Reactions were stopped by the
replacement of the medium with a stopping solution containing 0.2 M
HCl, 0.2% SDS and 2000 cpm of [14C]cAMP used
as recovery standard. The amount of [3H]cAMP
was determined as a percentage of the total labeled adenine nucleotide
pool according to Salomon (1979)
.
Measurement of Internalization. Internalization of receptors was determined by measuring loss of cell-surface immunoreactivity of HA-epitope-tagged receptors using an ELISA assay and by immunofluorescence microscopy.
ELISA Assay. 293-EBNA cells stably expressing the HA-epitope-tagged EP4 or EP2 receptor were grown in 12 plates. On the day of assay, the medium was replaced by DMEM buffered with 50 mM HEPES, pH 7.4. Cells were treated with PGE2 or vehicle for various times at 37° and incubations terminated by placing the plate in on ice for 5 min. Cells were fixed with 2% PFA for 10 min, washed, blocked, and incubated with anti-HA antibody [monoclonal HA 11 from Babco (Richmond, CA)] for 30 min. After washing, cells were incubated with horseradish peroxidase-conjugated secondary antibody for 30 min then washed and exposed to substrate O-phenylenediamine (Pierce, Rockford, IL) and hydrogen peroxide. Aliquots were transferred to 96-well plates, the reaction stopped by adding sulfuric acid, and read at 450 nm on a microtitre plate reader. Results were expressed relative to the value obtained with untreated cells as percent surface HA immunoreactivity.
Immunofluorescence Confocal Microscopy. 293-EBNA cells stably expressing HA-tagged receptors were grown in 35-mm dishes on coverslips. Cells were washed with PBS and treated with PGE2 for various times and at various concentrations. Cells were fixed and prepared by the following protocols to examine disappearance of receptors from the surface and appearance of receptors inside the cell using immunofluorescence confocal microscopy.
Detection of Surface Receptors. Cells were incubated with HA specific antibody (monoclonal HA 11 from Babco) at a 1:500 dilution for 30 min at 4°C in DMEM with 1% BSA and then washed twice with HBSS. The cells were warmed to 37°C and treated with or without 100 nM PGE2 for the indicated times in 0.5% BSA, 20 mM HEPES, pH 7.4 and then fixed with 2% PFA at room temperature for 10 min. The cells were washed three times with HBSS and blocked for 30 min at 37°C with PBS containing 5% nonfat milk (blotto). Goat anti-mouse fluorescein isothiocyanate-conjugated secondary antibody (Molecular Probes, Eugene, OR) was added at a dilution of 1:150 in BLOTTO for 30 min at 37°C. The cells were washed three times with HBSS. The coverslips were mounted on slides using slow-fade mounting medium (Molecular Probes).
Detection of Internalized Receptors. Cells were incubated with HA-specific antibody (monoclonal HA 16B12 from Babco, Richmond, CA) at a 1:500 dilution for 30 min at 4°C in DMEM with 1% BSA. The cells were washed twice with HBSS. The cells were warmed to 37°C and treated with or without 100 nM PGE2 for the indicated times in 0.5% BSA, 20 mM HEPES, pH 7.4 and then fixed with 2% PFA at room temperature for 10 min. To mask surface receptors, unconjugated goat antimouse IgG (Jackson Immunoresearch, West Grove, PA) was incubated with the cells for 60 min at 37°C at a dilution of 1:25. The cells were then washed six times with HBSS and permeabilized with 0.05% Triton X-100 in PBS for 10 min at room temperature. After blocking for 30 min with BLOTTO containing 0.05% Triton X-100, the secondary fluorescein isothiocyanate-conjugated antibody was added (1:150) in BLOTTO for 30 min at 37°C. Cells were washed six times with PBS containing 0.05% Triton X-100 and the last wash left for 30 min at 37°C. The cells were fixed with 2% PFA at room temperature for 10 min, washed three times with HBSS, and mounted on slides with coverslips using Slow-fade mounting medium.
Confocal Microscopy. Fluorescence was examined using a Leica TCS-NT confocal microscope. Single optical sections across cells are presented. Only a few cells are shown in each case; the cells are representative of the whole field. The photomultiplier gain and magnification were kept constant for each set of photographs to permit comparison among them.
| |
Results |
|---|
|
|
|---|
The C-terminal tails of the prostaglandin EP2 and EP4 receptors
are compared in Fig. 1. Hydropathy
analysis indicates that the C terminus of EP2 begins around residue
318, comprising 40 amino acids that include 10 serine and threonine
residues. The C terminus of EP4 begins around residue 350, comprising
148 amino acids that include 36 serine and threonine residues. Fig. 1
also illustrates the position of sites where truncation mutations were made in EP4 and the positions of serine and threonine residues that
were mutated.
|
Comparison of EP2 and EP4 Receptor Internalization by ELISA.
HA-tagged EP2 and EP4 prostaglandin receptors were expressed separately
in 293-EBNA cells. Addition of the HA-epitope tag to either receptor
did not affect its ability to generate cAMP and the
EC50 values of the receptors were unchanged (data
not shown). Typically, we observe values of between 2 and 3 nM for the
EC50 values of both EP2 and EP4 receptors. To
examine internalization, the cells were challenged with 1 µM
PGE2 for times ranging from 0 to 60 min and the
amount of remaining surface HA antigen was determined by an ELISA at
each time. As shown in Fig. 2, the EP4 receptor underwent rapid internalization to the extent of 40% with a
half-time of just a few minutes. By contrast, the EP2 receptor was not
internalized to any extent even after 60-min exposure to agonist. We
also examined the dose-response relationship for internalization of the
EP4 receptor after 30 min exposure to PGE2. The
EC50 for internalization of EP4 was 5 nM (data
not shown).
|
Comparison of EP2 and EP4 Receptor Internalization by Immunofluorescence Confocal Microscopy. In a parallel series of studies, we measured internalization of the transfected HA-tagged EP2 and EP4 receptor by confocal microscopy. We used different procedures to examine 1) receptors only on the surface and 2) receptors that had been internalized.
Fig. 3 shows the time course of disappearance of the wild-type receptor from the surface and the time course of appearance in transfected 293-EBNA cells after exposure to 100 nM PGE2. Disappearance of surface receptor is complemented by an increase in intracellular fluorescence with labeled receptor appearing in punctate regions inside the cell, which presumably represent early endosomes. The process shows a rapid time course similar to that observed by ELISA.
|
|
Examination of the Role of the C Terminus of EP4 in Internalization. To examine the role of the C terminus and to examine structural determinants involved in internalization of the EP4 receptor we created a number of truncation mutations that are illustrated in Fig. 1.
The wild-type receptor is designated t488 to indicate that it was truncated at the native stop codon to remove the 3'-untranslated tail. Other forms of the receptor were truncated at amino acid 383, 369, or 350 and are designated t383, t369, and t350. The truncations were characterized in previous studies from this laboratory (Bastepe and Ashby, 1999
|
|
Examination of the Role of C-Terminal Serine and Threonine Residues
in Internalization of EP4.
For many G protein-coupled receptors,
the presence of serine or threonine phosphorylation sites is important
for desensitization and internalization. In previous studies, we
examined the mutant S370-382A, in which six serine residues between
positions 370 and 382 were mutated to alanine in the full-length
receptor. We showed that mutation of the six serines abolishes rapid
agonist-induced desensitization. However, examination of the HA-tagged
mutant S370-382A (HA-S370-382A) by ELISA analysis after exposure to
PGE2 showed that it displayed a similar extent
and rate of internalization as the wild-type receptor, indicating that
the six serine residues in this region play no role in internalization
(Fig. 7). The result was confirmed by
examination of cells expressing HA-S370-382A by confocal
immunofluorescence microscopy (Fig. 8).
Challenge with 100 nM PGE2 for 30 min resulted in
marked disappearance of HA-S370-382A from the surface of the cell and a
pronounced increase in intracellular fluorescence in vesicles.
Intermediate time points showed that internalization took place rapidly
with a time course (not shown) similar to that observed in the ELISA
assay.
|
|
| |
Discussion |
|---|
|
|
|---|
In the current work we have shown that epitope-tagged prostaglandin EP4 receptor undergoes rapid internalization in response to PGE2, whereas the epitope-tagged prostaglandin EP2 receptor does not. Internalization of epitope-tagged forms of the receptors was measured by ELISA analysis, which showed that EP2 is not internalized after 1-h exposure to PGE2, whereas EP4 internalizes rapidly with a t1/2 of 2 min, to the extent of 40% loss of surface EP4 receptor. The results were closely paralleled in time-course experiments showing disappearance of cell surface EP4 receptor and appearance of internalized receptor by immunofluorescence confocal microscopy.
The role of the carboxyl tail in desensitization and internalization has been demonstrated for a number of G protein coupled receptors using studies of truncated receptors and site-directed mutagenesis. In the case of the EP4 receptor, we have previously shown that the C terminus plays a role in rapid agonist-induced desensitization of adenylyl cyclase activity. To examine the role of the C terminus in internalization of EP4, we prepared an epitope-tagged form of the receptor truncated at amino acid 350 (HA-t350), close to the proximal end of the C terminus. Studies by both ELISA analysis and immunofluorescence confocal microscopy demonstrated that mutant t350 underwent minimal internalization. Further deletion mutants were studied. Truncation of the receptor at residue 369 also attenuated internalization, whereas truncation at residue 383 had little effect.
The results indicate that the region of the C terminus between residues
350 and 383 may be important in internalization. We have previously
shown that the same region seems to be involved in agonist-induced
desensitization of adenylyl cyclase. Within this 33-amino-acid stretch
are 10 serines and one threonine, which are potential sites for
phosphorylation. In previous studies (Bastepe and Ashby, 1999
), we
mutated the six serines in the region 370 to 382 to alanine to generate
the mutant S370-382A, a full-length form of the receptor with
serine-to-alanine mutations at positions 370, 371, 374, 377, 379, and
382. Mutant S370-382A was impaired in agonist-induced desensitization.
However, in the current study we have shown by ELISA analysis that an
epitope-tagged form of S370-382A undergoes internalization to the same
extent and at the same rate as the native receptor. The finding was
confirmed by immunofluorescence microscopy, which showed significant
internalization of the mutant S370-382A receptor.
We also mutated the remaining four serines and one threonine residue in the region 350 to 383, which are located between residues 354 and 369. The full-length mutant receptor, designated S354-369A, contained the amino acid substitutions S354A, S359A, S364A, S366G, and T369A. The epitope-tagged mutant, designated HA-S354-369A, underwent internalization to the same extent as the wild-type receptor.
We examined a further mutant, designated S354-382A, containing amino acid substitutions S354A, S359A, S364A, S366G, T369A, S370A, S371A, S374A, S377A, S379A, and S382A. This mutant again was a full-length receptor, combining the mutations in S354-369A with the mutations in S370-382A. Mutant S354-382A, containing a total of 10 serine mutations and 1 threonine mutation in the C terminus, internalized to the same extent as the wild-type. We conclude that the C terminus of the EP4 receptor is involved in internalization; however, serine and threonine residues do not seem to be involved.
In common with findings with numerous G protein-coupled receptors, the
results support the idea that the C-tail is an important domain in
internalization. In general, receptors with short C-tails do not
undergo internalization, whereas receptor forms with long C-tails do
internalize. Similarly, truncation of the C-tail often leads to loss of
internalization. For example, our results may be compared with those
described for the thromboxane A2 receptor (TP). The human TP receptor
seems to be encoded by a single gene that can be alternatively spliced
in the C-tail to give rise to a short isoform TP
(343 residues) and
a long isoform TP
(407 residues). Benovic and coworkers have
examined internalization of the isoforms (Parent et al., 1999
). Using
ELISA and immunofluorescence microscopy, they demonstrated that TP
but not TP
underwent agonist-induced internalization when expressed
in HEK 293 cells.
Numerous studies have been directed toward identification of particular
residues in the C-tail involved in internalization. For example, a
short sequence SSNGNTGEQS located in the mid-region of the C-tail of
the
2AR has been identified as being potentially important for
agonist-mediated sequestration (Hausdorff et al., 1991
). Mutation of
Ser355, Thr356, Ser360, and Thr364 markedly decreased internalization
of the receptor. There is a somewhat homologous sequence (SSQGQDSESV)
in the C-tail of EP4. However, this sequence is located close to the
distal end of the C terminus and its removal in the truncation t383 has
no effect on internalization.
In the AT1A angiotensin receptor, the motif Ser-Thr-Leu (residues
335-337) seems to be involved (Thomas et al., 1995
), whereas in the m3
muscarinic receptor, Thr550, Thr553, and Thr554 are implicated (Yang et
al., 1995
). In the case of the gastrin-releasing peptide receptor,
multiple serine and threonine residues distal to a putative
palmitoylated cysteine residue have been shown to regulate
internalization rate (Benya et al. 1993
). In the case of the EP4
receptor, mutation of serine (and threonine) residues in two groups of
six and five had no effect on internalization.
Although specific amino acid residues and sequence motifs have been
implicated in G protein-coupled desensitization and internalization, numerous studies similar to ours seem to indicate that the mechanisms responsible for the two processes are distinct. For example,
substitution of four serine and threonine residues in the carboxyl
terminus of the N-formyl peptide chemoattractant receptor
resulted in a mutant that was unable to desensitize but continued to
internalize in a manner similar to that of the wild-type receptor
(Maestes et al., 1999
). This was also true for the parathyroid hormone receptor, in which alanine mutagenesis of six serine residues abolished
phosphorylation but had no effect on the rate and extent of
internalization (Malecz et al., 1998
). Similarly, certain residues can
be mutated in the C-tail of the
-adrenergic receptor that affect
desensitization without affecting sequestration (Campbell et al.,
1991
), and mutation of individual serine residues in the C-terminal
tail of the lutropin/choriogonadotropin receptor shows distinct
structural requirements for agonist-induced uncoupling and
agonist-induced internalization (Lazari et al., 1998
). Pals-Rylaarsdam et al. (1995)
showed that desensitization and internalization of the m2
muscarinic acetylcholine receptor are directed by independent mechanisms. In the case of the prostaglandin EP4 receptor, mutation of
serine residues in the region 370 to 382 abolishes desensitization (Bastepe and Ashby, 1999
) but has no effect on internalization.
Residues other than serine and threonine have been shown to be involved
in internalization. Dileucine motifs located in the C terminus have
been implicated in internalization of certain receptors, including the
-adrenergic receptor (Gabilondo et al., 1997
). There are three
dileucine motifs in the EP4 receptor C-tail: Leu 395/396, Leu 414/415,
and Leu 452/453. However, all of these residues are eliminated by
truncation of the receptor at residue 383 with little effect on
internalization, indicating that none is important for this process.
Lack of involvement of serine and threonine residues tends to imply a
mechanism of internalization distinct from that described for the
-adrenergic receptor. The latter involves agonist-induced phosphorylation of the receptor, followed by binding of
-arrestin, binding of the phosphorylated receptor-arrestin-complex to clathrin and
endocytosis by clathrin-coated vesicles (Ferguson et al., 1998
; Gagnon
et al., 1998
; Lefkowitz et al., 1998
). Other mechanisms, represented by
angiotensin II type 1A receptor, do not require
-arrestin or dynamin
I (Zhang et al., 1996
; Ferguson et al., 1998
) and internalization seems
to proceed via noncoated vesicles (caveolae). Studies are underway in
this laboratory to determine the pathway of internalization of the
prostaglandin EP4 receptor.
| |
Footnotes |
|---|
Received April 8, 2000; Accepted September 7, 2000
This work was supported by a Grant-in-Aid from the Southeastern Pennsylvania Chapter of the American Heart Association and by a Grant-in Aid from the American Heart Association National Organization.
Send reprint requests to: Barrie Ashby, Ph.D., Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140. E-mail: bashby00{at}nimbus.temple.edu
| |
Abbreviations |
|---|
PGE2, prostaglandin E2; ELISA, enzyme-linked immunosorbent assay; HA, hemagglutinin; PCR, polymerase chain reaction; HEK, human embryonic kidney; DMEM, Dulbecco's modified Eagle's medium; EBNA, Epstein-Barr virus nuclear antigen; IBMX, 3-isobutyl-1-methylxanthine; PFA, paraformaldehyde; HBSS, Hank's balanced salt solution; BLOTTO, bovine lacto transfer optimizer.
| |
References |
|---|
|
|
|---|
2-adrenergic receptor.
J Biol Chem
273:
6976-6981
-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization.
J Biol Chem
271:
18302-18305This article has been cited by other articles:
![]() |
H. Fujino, W. Xu, and J. W. Regan Prostaglandin E2 Induced Functional Expression of Early Growth Response Factor-1 by EP4, but Not EP2, Prostanoid Receptors via the Phosphatidylinositol 3-Kinase and Extracellular Signal-regulated Kinases J. Biol. Chem., March 28, 2003; 278(14): 12151 - 12156. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Konger, G. A. Scott, Y. Landt, J. H. Ladenson, and A. P. Pentland Loss of the EP2 Prostaglandin E2 Receptor in Immortalized Human Keratinocytes Results in Increased Invasiveness and Decreased Paxillin Expression Am. J. Pathol., December 1, 2002; 161(6): 2065 - 2078. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Penn, R. M. Pascual, Y.-M. Kim, S. J. Mundell, V. P. Krymskaya, R. A. Panettieri Jr., and J. L. Benovic Arrestin Specificity for G Protein-coupled Receptors in Human Airway Smooth Muscle J. Biol. Chem., August 24, 2001; 276(35): 32648 - 32656. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fujino, K. A. West, and J. W. Regan Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 J. Biol. Chem., January 18, 2002; 277(4): 2614 - 2619. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||